Precigen, Inc. (PGEN)
NASDAQ: PGEN · Real-Time Price · USD
4.470
+0.250 (5.92%)
At close: Nov 6, 2026, 4:00 PM EST
4.485
+0.015 (0.34%)
Pre-market: Nov 9, 2026, 6:40 AM EST
Precigen Revenue
Precigen had revenue of $74.15M in the quarter ending September 30, 2026, with 2,437.58% growth. This brings the company's total for the last twelve months to $156.94M, up 2,387.61% year-over-year. In the year 2025, Precigen had annual revenue of $9.68M with 146.73% growth. That makes Precigen the 19,259th largest company in the world by revenue and 3,019th in the United States.
Revenue (ttm)
$156.94M
Revenue Growth
+2,387.61%
P/S Ratio
10.21
Revenue / Employee
$980,894
Employees
160
Market Cap
1.60B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.68M | 5.76M | 146.73% |
| Dec 31, 2024 | 3.93M | -2.30M | -36.95% |
| Dec 31, 2023 | 6.23M | -20.68M | -76.87% |
| Dec 31, 2022 | 26.91M | 12.64M | 88.61% |
| Dec 31, 2021 | 14.27M | -88.91M | -86.17% |
| Dec 31, 2020 | 103.18M | 12.46M | 13.73% |
| Dec 31, 2019 | 90.72M | -60.46M | -39.99% |
| Dec 31, 2018 | 151.18M | -68.29M | -31.11% |
| Dec 31, 2017 | 219.46M | 28.54M | 14.95% |
| Dec 31, 2016 | 190.93M | 17.32M | 9.98% |
| Dec 31, 2015 | 173.61M | 101.68M | 141.35% |
| Dec 31, 2014 | 71.93M | 71.13M | 8,891.25% |
| Dec 31, 2013 | 800.00K | -12.97M | -94.19% |
| Dec 31, 2012 | 13.77M | 5.76M | 71.90% |
| Dec 31, 2011 | 8.01M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Ultragenyx Pharmaceutical | 730.00M |
| Nurix Therapeutics | 701.94M |
| Immunocore Holdings | 430.78M |
| Intellia Therapeutics | 52.89M |
| Generate Biomedicines | 26.48M |
| uniQure | 20.17M |
| Nanobiotix | 13.15M |
| ADARx Pharmaceuticals | 6.13M |
PGEN News
- 4 days ago - Precigen price target raised to $12 from $11 at Citizens - TheFly
- 4 days ago - Precigen reports Q3 EPS 8c vs. ($1.06) last year - TheFly
- 4 days ago - Precigen Earnings Call Transcript: Q3 2026 - Transcripts
- 4 days ago - Precigen Quarterly report: Q3 2026 - Filings
- 4 days ago - Precigen Earnings release: Q3 2026 - Filings
- 4 days ago - Precigen Reports Third Quarter 2026 Results Highlighted by Strong Sequential PAPZIMEOS Revenue Growth and Positive Cash Flow Ahead of Guidance - PRNewsWire
- 6 days ago - Precigen falls -23.6% - TheFly
- 6 days ago - Precigen falls -26.5% - TheFly